Table 2.
Clinically significant toxicities with combination PD-1 and CTLA-4 blockade and anti-PD-1 resumption
| irAEs with CTLA-4 + PD-1 blockade |
irAEs with anti-PD-1 resumption (recurrent or de novo) |
|||
|---|---|---|---|---|
| irAE | All grade irAE, n (%) | Grade 3/4 irAE, n (%) | All grade irAE, n (%) | Grade 3/4 irAE, n (%) |
| Colitis | 33 (41) | 20 (25) | 6 (8) | 2 (3) |
| Hepatitis | 29 (36) | 19 (24) | 8 (10) | 5 (7) |
| Hypophysitis | 5 (6) | 2 (3) | 2 (3) | 1 (1) |
| Dermatitis/rash | 5 (6) | 3 (4) | 6 (8) | 2 (3)a |
| Pneumonitis | 3 (4) | 1 (1) | 4 (5) | – |
| Elevated lipase | 4 (5)b | 4 (5) | 3 (5) | 2 (3)b |
| Nephritis | 2 (3) | 1 (1) | 1 (1) | – |
| Neurologic | 2 (3) | 1 (1) | – | – |
| ITP | 1 (1) | 1 (1) | – | – |
| Other | 7 (9) | 2 (3) | 8 (10) | 2 (3)c |
a
Includes one patient with grade 5 Stevens–Johnson Syndrome.
b
Two patients with clinical pancreatitis.
c
Grade 3 type 1 diabetes and grade 3 arthralgias.
CTLA-4, cytotoxic T-lymphocyte antigen 4; PD-1, programmed death 1; irAE, immune-related adverse event.